Trials / Terminated
TerminatedNCT03522142
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB081776 | INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose. |
| DRUG | INCMGA00012 | INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks |
Timeline
- Start date
- 2018-08-27
- Primary completion
- 2025-09-10
- Completion
- 2025-09-10
- First posted
- 2018-05-11
- Last updated
- 2025-10-09
Locations
18 sites across 5 countries: United States, Denmark, Netherlands, Norway, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03522142. Inclusion in this directory is not an endorsement.